Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Comment by forhandlarenon Mar 26, 2021 1:59am
232 Views
Post# 32884306

RE:RE:Shareprice

RE:RE:SharepriceBased on the NR's at least two batches of 20kg have been produced in France - probably more - and at least one much bigger (volume unknown) in China.

Each kilo represents 500 000 ml - Howard has stated 10000 tubes of 50 ml, but R+F put it in 15 ml.

Their market is currently 300K agents with 2 million customers, but they have just started to build their business in Japan. In addition there's internet sales not tied to the agents. Let's assume 3 million users.

Most of the users will try the product at least once, many of them on a regular basis. Let's assume 50 percent and 4 tubes annually (60 ml).

1 500 000 users x 60 ml = 90 million ml
90 million ml / 500 000 = 180 kg
180 kg x 10 000 CAD = 1 800 000 CAD

The revenue will cover about 50 percent of the burn rate (including production costs).

I assume that the primary goal with the R+F deal is to get street cred and revenue is welcome but secondary.

The upcoming multiple deals with this low concentration should be more profitable, not to mention the pharmaceutical grade in the works with clinical results due withon a week or two.


<< Previous
Bullboard Posts
Next >>